journal article·2018-10-31

Passive delivery of protein drugs through transdermal route

Bivek Chaulagain, Ankit Jain, Ankita Tiwari, Amit Verma, Sanjay K. Jain

Publisher page

Abstract

Skin is the largest external organ in the human body but its use for therapeutic purposes has been minimal. Stratum corneum residing on the uppermost layer of the skin provides a tough barrier to transport the drugs across the skin. Very small group of drugs sharing Lipinski properties, i.e. drugs having molecular weight not larger than 500 Da, having high lipophilicity and optimum polarity are fortunate enough to be used on skin therapeutics. But, at a time where modern therapeutics is slowly shifting from use of small molecular drugs towards the use of macromolecular therapeutic agents such as peptides, proteins and nucleotides in origin, skin therapeutics need to be evolved accordingly to cater the delivery of these agents. Physical technologies like iontophoresis, laser ablation, micro-needles and ultrasound, etc. have been introduced to enhance skin permeability. But their success is limited due to their complex working mechanisms and involvement of certain irreversible skin damage in some or other way. This review therefore explores the delivery strategies for transport of mainly peptide and protein drugs that do not involve any injuries (non-invasive) to the skin termed as passive delivery techniques. Chemical enhancers, nanocarriers, certain biological peptides and miscellaneous approaches like prodrugs are also thoroughly reviewed for their applications in protein delivery.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advancements in Transdermal Drug Delivery · RNA Interference and Gene Delivery · Lipid Membrane Structure and Behavior

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutical Sciences, Pharmaceutics Research Projects Laboratory, Dr. Hari Singh Gour Central University

Institute of Pharmaceutical Research, GLA University

References (100+)

Show source-provided references
1. 10.1038/nrd436310.1038/nrd4363 ↗
2. 10.1016/j.drudis.2015.06.00710.1016/j.drudis.2015.06.007 ↗
3. 10.1517/17425247.2016.113003410.1517/17425247.2016.1130034 ↗
4. 10.1016/j.jconrel.2014.05.02210.1016/j.jconrel.2014.05.022 ↗
5. 10.1016/j.drudis.2014.09.00310.1016/j.drudis.2014.09.003 ↗
6. 10.4155/tde.15.6010.4155/tde.15.60 ↗
7. 10.1208/s12249-011-9601-610.1208/s12249-011-9601-6 ↗
8. 10.1016/j.ejpb.2017.06.01910.1016/j.ejpb.2017.06.019 ↗
9. 10.1007/s11095-012-0852-z10.1007/s11095-012-0852-z ↗
10. 10.1016/B978-0-12-384935-9.10004-510.1016/B978-0-12-384935-9.10004-5 ↗
11. 10.1159/00035181510.1159/000351815 ↗
12. Bouwstra JA, Dubbelaar FE, Gooris GS, et al. The lipid organisation in the skin barrier. Acta Derm Venereol Suppl (Stockh). 2000;208:23–30.
13. 10.1016/S0163-7827(02)00028-010.1016/S0163-7827(02)00028-0 ↗
14. 10.1016/S0169-409X(02)00114-X10.1016/S0169-409X(02)00114-X ↗
15. 10.1111/ics.1216210.1111/ics.12162 ↗
16. 10.1093/intimm/dxv01310.1093/intimm/dxv013 ↗
17. 10.1016/j.bbalip.2013.11.00610.1016/j.bbalip.2013.11.006 ↗
18. 10.1046/j.1523-1747.2003.12359.x10.1046/j.1523-1747.2003.12359.x ↗
19. 10.1111/j.1467-2494.1988.tb00028.x10.1111/j.1467-2494.1988.tb00028.x ↗
20. 10.1016/j.addr.2012.09.03210.1016/j.addr.2012.09.032 ↗
21. 10.1007/978-3-662-47039-8_210.1007/978-3-662-47039-8_2 ↗
22. 10.4314/tjpr.v8i2.4452710.4314/tjpr.v8i2.44527 ↗
23. 10.1016/j.bmcl.2005.12.08610.1016/j.bmcl.2005.12.086 ↗
24. 10.2174/15672011280023458510.2174/156720112800234585 ↗
25. 10.1023/A:101190602290310.1023/A:1011906022903 ↗
26. 10.1002/jps.1013210.1002/jps.10132 ↗
27. 10.1021/mp300441c10.1021/mp300441c ↗
28. 10.1016/S0168-3659(96)01618-510.1016/S0168-3659(96)01618-5 ↗
29. 10.1016/j.jconrel.2014.12.00610.1016/j.jconrel.2014.12.006 ↗
30. 10.1002/bip.2147610.1002/bip.21476 ↗
31. 10.1002/adhm.20150063410.1002/adhm.201500634 ↗
32. 10.1111/j.1476-5381.2009.00057.x10.1111/j.1476-5381.2009.00057.x ↗
33. 10.1016/j.addr.2004.10.01010.1016/j.addr.2004.10.010 ↗
34. 10.1016/j.molmed.2012.04.01210.1016/j.molmed.2012.04.012 ↗
35. 10.1002/iub.29710.1002/iub.297 ↗
36. 10.1007/978-1-60761-919-2_210.1007/978-1-60761-919-2_2 ↗
37. 10.1007/978-1-60761-919-2_110.1007/978-1-60761-919-2_1 ↗
38. 10.1016/j.bbamem.2006.05.01310.1016/j.bbamem.2006.05.013 ↗
39. 10.1074/jbc.M00754020010.1074/jbc.M007540200 ↗
40. 10.1042/BC2007011610.1042/BC20070116 ↗
41. 10.1096/fasebj.12.1.6710.1096/fasebj.12.1.67 ↗
42. 10.1016/S0022-3565(24)29672-510.1016/S0022-3565(24)29672-5 ↗
43. 10.1007/s11095-014-1586-x10.1007/s11095-014-1586-x ↗
44. 10.1021/jp412739p10.1021/jp412739p ↗
45. 10.1016/S0891-5849(01)00734-110.1016/S0891-5849(01)00734-1 ↗
46. 10.1016/j.jconrel.2015.05.12810.1016/j.jconrel.2015.05.128 ↗
47. 10.1111/cbdd.1200810.1111/cbdd.12008 ↗
48. 10.1021/acs.biomac.5b0152410.1021/acs.biomac.5b01524 ↗
49. 10.1167/iovs.16-2007210.1167/iovs.16-20072 ↗
50. 10.1016/j.jconrel.2014.08.01410.1016/j.jconrel.2014.08.014 ↗
51. 10.3109/09687688.2010.52220310.3109/09687688.2010.522203 ↗
52. 10.1074/jbc.M20954820010.1074/jbc.M209548200 ↗
53. 10.1021/bi501392n10.1021/bi501392n ↗
54. 10.1007/978-3-662-47039-8_2110.1007/978-3-662-47039-8_21 ↗
55. 10.1073/pnas.101615210810.1073/pnas.1016152108 ↗
56. 10.1016/j.jconrel.2013.10.00710.1016/j.jconrel.2013.10.007 ↗
57. 10.1016/j.jconrel.2014.11.01510.1016/j.jconrel.2014.11.015 ↗
58. 10.1073/pnas.84.15.544910.1073/pnas.84.15.5449 ↗
59. 10.1016/j.jconrel.2007.05.03110.1016/j.jconrel.2007.05.031 ↗
60. 10.1016/j.jpcs.2007.10.13810.1016/j.jpcs.2007.10.138 ↗
61. 10.1016/j.ijpharm.2008.05.04210.1016/j.ijpharm.2008.05.042 ↗
62. 10.1038/nbt119310.1038/nbt1193 ↗
63. 10.2174/138161282166615042814324310.2174/1381612821666150428143243 ↗
64. 10.3390/ijms1702018510.3390/ijms17020185 ↗
65. 10.1517/14712598.2.7.72310.1517/14712598.2.7.723 ↗
66. 10.1016/0024-3205(80)90268-410.1016/0024-3205(80)90268-4 ↗
67. 10.1016/0378-5173(84)90225-410.1016/0378-5173(84)90225-4 ↗
68. 10.1248/cpb.38.200310.1248/cpb.38.2003 ↗
69. 10.1016/j.ddtec.2005.05.00310.1016/j.ddtec.2005.05.003 ↗
70. 10.1016/0005-2736(92)90154-E10.1016/0005-2736(92)90154-E ↗
71. 10.1016/j.ijpharm.2006.12.00510.1016/j.ijpharm.2006.12.005 ↗
72. 10.1080/10837450.2017.133034510.1080/10837450.2017.1330345 ↗
73. 10.1208/s12249-015-0441-710.1208/s12249-015-0441-7 ↗
74. 10.3109/08982104.2015.109865910.3109/08982104.2015.1098659 ↗
75. 10.1016/S0005-2736(01)00369-810.1016/S0005-2736(01)00369-8 ↗
76. 10.1016/S0378-5173(99)00361-010.1016/S0378-5173(99)00361-0 ↗
77. 10.1208/pt06036410.1208/pt060364 ↗
78. 10.1016/S0005-2736(97)00177-610.1016/S0005-2736(97)00177-6 ↗
79. 10.1016/j.biomaterials.2005.05.09710.1016/j.biomaterials.2005.05.097 ↗
80. 10.1002/eji.183025124810.1002/eji.1830251248 ↗
81. 10.1007/978-3-662-47862-2_310.1007/978-3-662-47862-2_3 ↗
82. 10.1517/17425247.2.3.48910.1517/17425247.2.3.489 ↗
83. 10.1517/17425247.2011.55945810.1517/17425247.2011.559458 ↗
84. 10.1016/j.biotechadv.2015.01.01010.1016/j.biotechadv.2015.01.010 ↗
85. 10.1211/002235705571310.1211/0022357055713 ↗
86. 10.1016/j.jconrel.2010.04.02310.1016/j.jconrel.2010.04.023 ↗
87. 10.1159/00034108510.1159/000341085 ↗
88. 10.1016/S0169-409X(02)00116-310.1016/S0169-409X(02)00116-3 ↗
89. 10.1016/S0168-3659(96)01559-310.1016/S0168-3659(96)01559-3 ↗
90. 10.1016/j.addr.2011.01.01210.1016/j.addr.2011.01.012 ↗
91. 10.1016/j.biomaterials.2010.08.04610.1016/j.biomaterials.2010.08.046 ↗
92. 10.1038/sj.jid.570073310.1038/sj.jid.5700733 ↗
93. 10.1088/0957-4484/18/45/45510310.1088/0957-4484/18/45/455103 ↗
94. 10.2147/RRTD.S7580910.2147/RRTD.S75809 ↗
95. 10.1208/pt06024010.1208/pt060240 ↗
96. 10.18433/J3HW2B10.18433/J3HW2B ↗
97. 10.1134/S199507801504014X10.1134/S199507801504014X ↗
98. 10.1021/mp500676e10.1021/mp500676e ↗
99. 10.1111/srt.1222810.1111/srt.12228 ↗
100. 10.1111/j.1468-3083.2004.01180.x10.1111/j.1468-3083.2004.01180.x ↗